Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106


Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies.

Hutchinson JM, Mesa KA, Alexander DL, Yu B, O'Rourke SM, Limoli KL, Wrin T, Deeks SG, Berman PW.

Front Immunol. 2019 May 15;10:1021. doi: 10.3389/fimmu.2019.01021. eCollection 2019.


Identification and CRISPR/Cas9 Inactivation of the C1s Protease Responsible for Proteolysis of Recombinant Proteins Produced in CHO Cells.

Li SW, Yu B, Byrne G, Wright M, O'Rourke S, Mesa K, Berman PW.

Biotechnol Bioeng. 2019 Sep;116(9):2130-2145. doi: 10.1002/bit.27016. Epub 2019 Jun 10.


Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens.

Mesa KA, Yu B, Wrin T, Petropoulos CJ, Pogson GH, Alexander DL, Perez G, O'Rourke SM, Sinangil F, Robinson J, Conant MA, Berman PW.

PLoS One. 2019 Apr 10;14(4):e0213409. doi: 10.1371/journal.pone.0213409. eCollection 2019.


Production of a recombinant monoclonal antibody to Herpes Simplex Virus glycoprotein D for immunoaffinity purification of tagged proteins.

O'Rourke SM, Yu B, Morales JF, Didinger CM, Alexander DL, Vollmers C, Berman PW.

J Immunol Methods. 2019 Feb;465:31-38. doi: 10.1016/j.jim.2018.11.015. Epub 2018 Nov 28.


Development of a Stable MGAT1- CHO Cell Line to Produce Clade C gp120 With Improved Binding to Broadly Neutralizing Antibodies.

Doran RC, Yu B, Wright M, O'Rourke SM, Yin L, Richardson JM, Byrne G, Mesa KA, Berman PW.

Front Immunol. 2018 Oct 5;9:2313. doi: 10.3389/fimmu.2018.02313. eCollection 2018.


CRISPR/Cas9 gene editing for the creation of an MGAT1-deficient CHO cell line to control HIV-1 vaccine glycosylation.

Byrne G, O'Rourke SM, Alexander DL, Yu B, Doran RC, Wright M, Chen Q, Azadi P, Berman PW.

PLoS Biol. 2018 Aug 29;16(8):e2005817. doi: 10.1371/journal.pbio.2005817. eCollection 2018 Aug.


Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine production.

O'Rourke SM, Byrne G, Tatsuno G, Wright M, Yu B, Mesa KA, Doran RC, Alexander D, Berman PW.

PLoS One. 2018 Aug 2;13(8):e0197656. doi: 10.1371/journal.pone.0197656. eCollection 2018.


Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies.

Doran RC, Tatsuno GP, O'Rourke SM, Yu B, Alexander DL, Mesa KA, Berman PW.

PLoS One. 2018 Apr 24;13(4):e0196370. doi: 10.1371/journal.pone.0196370. eCollection 2018.


HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.

Yates NL, deCamp AC, Korber BT, Liao HX, Irene C, Pinter A, Peacock J, Harris LJ, Sawant S, Hraber P, Shen X, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Berman PW, Robb ML, Pantaleo G, Zolla-Pazner S, Haynes BF, Alam SM, Montefiori DC, Tomaras GD.

J Virol. 2018 Mar 28;92(8). pii: e01843-17. doi: 10.1128/JVI.01843-17. Print 2018 Apr 15.


Effects of Cross-Presentation, Antigen Processing, and Peptide Binding in HIV Evasion of T Cell Immunity.

Frey BF, Jiang J, Sui Y, Boyd LF, Yu B, Tatsuno G, Billeskov R, Solaymani-Mohammadi S, Berman PW, Margulies DH, Berzofsky JA.

J Immunol. 2018 Mar 1;200(5):1853-1864. doi: 10.4049/jimmunol.1701523. Epub 2018 Jan 26.


Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.

Wang K, Tomaras GD, Jegaskanda S, Moody MA, Liao HX, Goodman KN, Berman PW, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Haynes BF, Cohen JI.

J Virol. 2017 Sep 12;91(19). pii: e00411-17. doi: 10.1128/JVI.00411-17. Print 2017 Oct 1.


V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.

Perez LG, Martinez DR, deCamp AC, Pinter A, Berman PW, Francis D, Sinangil F, Lee C, Greene K, Gao H, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, O'Connell RJ, Robb ML, Michael NL, Kim JH, Gilbert P, Montefiori DC.

PLoS One. 2017 Jul 5;12(7):e0180720. doi: 10.1371/journal.pone.0180720. eCollection 2017.


Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women.

Gilbert PB, Excler JL, Tomaras GD, Carpp LN, Haynes BF, Liao HX, Montefiori DC, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Kijak GH, Tovanabutra S, Francis DP, Lee C, Sinangil F, Berman PW, Premsri N, Kunasol P, O'Connell RJ, Michael NL, Robb ML, Morrow R, Corey L, Kim JH.

PLoS One. 2017 May 11;12(5):e0176428. doi: 10.1371/journal.pone.0176428. eCollection 2017.


Peptide Targeted by Human Antibodies Associated with HIV Vaccine-Associated Protection Assumes a Dynamic α-Helical Structure.

Aiyegbo MS, Shmelkov E, Dominguez L, Goger M, Battacharya S, deCamp AC, Gilbert PB, Berman PW, Cardozo T.

PLoS One. 2017 Jan 20;12(1):e0170530. doi: 10.1371/journal.pone.0170530. eCollection 2017.


Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.

Morales JF, Yu B, Perez G, Mesa KA, Alexander DL, Berman PW.

Mol Immunol. 2016 Sep;77:14-25. doi: 10.1016/j.molimm.2016.07.003. Epub 2016 Jul 21.


Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses.

O'Rourke SM, Sutthent R, Phung P, Mesa KA, Frigon NL, To B, Horthongkham N, Limoli K, Wrin T, Berman PW.

PLoS One. 2015 Mar 20;10(3):e0119608. doi: 10.1371/journal.pone.0119608. eCollection 2015.


Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.

Doran RC, Morales JF, To B, Morin TJ, Theolis R Jr, O'Rourke SM, Yu B, Mesa KA, Berman PW.

Mol Immunol. 2014 Nov;62(1):219-226. doi: 10.1016/j.molimm.2014.06.025. Epub 2014 Jul 11.


HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1.

Morales JF, Morin TJ, Yu B, Tatsuno GP, O'Rourke SM, Theolis R Jr, Mesa KA, Berman PW.

J Biol Chem. 2014 Jul 25;289(30):20526-42.


Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.

Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, Berman PW, Alpert MD, Evans DT, O'Connell RJ, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Pinter A, Zolla-Pazner S, Gilbert PB, Nabel GJ, Michael NL, Kim JH, Montefiori DC, Haynes BF, Tomaras GD.

Sci Transl Med. 2014 Mar 19;6(228):228ra39. doi: 10.1126/scitranslmed.3007730.


Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.

Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, Wenschuh H, Zerweck J, Greene K, Gao H, Berman PW, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Robb ML, Michael NL, Kim JH, Zolla-Pazner S, Haynes BF, Mascola JR, Self S, Gilbert P, Montefiori DC.

PLoS One. 2013 Sep 26;8(9):e75665. doi: 10.1371/journal.pone.0075665. eCollection 2013.


Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion.

Alam SM, Liao HX, Tomaras GD, Bonsignori M, Tsao CY, Hwang KK, Chen H, Lloyd KE, Bowman C, Sutherland L, Jeffries TL Jr, Kozink DM, Stewart S, Anasti K, Jaeger FH, Parks R, Yates NL, Overman RG, Sinangil F, Berman PW, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Karasavva N, Rerks-Ngarm S, Kim JH, Michael NL, Zolla-Pazner S, Santra S, Letvin NL, Harrison SC, Haynes BF.

J Virol. 2013 Feb;87(3):1554-68. doi: 10.1128/JVI.00718-12. Epub 2012 Nov 21.


Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.

O'Rourke SM, Schweighardt B, Phung P, Mesa KA, Vollrath AL, Tatsuno GP, To B, Sinangil F, Limoli K, Wrin T, Berman PW.

J Virol. 2012 Nov;86(22):12105-14. doi: 10.1128/JVI.01352-12. Epub 2012 Aug 29.


Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials.

Yu B, Morales JF, O'Rourke SM, Tatsuno GP, Berman PW.

PLoS One. 2012;7(8):e43903. doi: 10.1371/journal.pone.0043903. Epub 2012 Aug 22.


Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 binding.

Nakamura GR, Fonseca DP, O'Rourke SM, Vollrath AL, Berman PW.

PLoS One. 2012;7(6):e39045. doi: 10.1371/journal.pone.0039045. Epub 2012 Jun 13.


Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, Greene K, Gao H, LaBranche CC, Andrews C, Polonis VR, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Self SG, Berman PW, Francis D, Sinangil F, Lee C, Tartaglia J, Robb ML, Haynes BF, Michael NL, Kim JH.

J Infect Dis. 2012 Aug 1;206(3):431-41. doi: 10.1093/infdis/jis367. Epub 2012 May 25.


Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH.

N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.


Phylodynamics of HIV-1 from a phase III AIDS vaccine trial in Bangkok, Thailand.

Pérez-Losada M, Jobes DV, Sinangil F, Crandall KA, Arenas M, Posada D, Berman PW.

PLoS One. 2011 Mar 10;6(3):e16902. doi: 10.1371/journal.pone.0016902.


Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies.

Smith DH, Winters-Digiacinto P, Mitiku M, O'Rourke S, Sinangil F, Wrin T, Montefiori DC, Berman PW.

PLoS One. 2010 Aug 11;5(8):e12076. doi: 10.1371/journal.pone.0012076.


Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus.

O'Rourke SM, Schweighardt B, Phung P, Fonseca DP, Terry K, Wrin T, Sinangil F, Berman PW.

J Virol. 2010 Nov;84(21):11200-9. doi: 10.1128/JVI.00790-10. Epub 2010 Aug 11.


Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.

Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D'Souza P, Rodriguez-Chavez IR, DeCamp A, Giganti M, Berman PW, Self SG, Montefiori DC.

J Infect Dis. 2010 Aug 15;202(4):595-605. doi: 10.1086/654816.


Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites.

Yu B, Fonseca DP, O'Rourke SM, Berman PW.

J Virol. 2010 Feb;84(3):1513-26. doi: 10.1128/JVI.01765-09. Epub 2009 Nov 25.


Phylodynamics of HIV-1 from a phase-III AIDS vaccine trial in North America.

Pérez-Losada M, Jobes DV, Sinangil F, Crandall KA, Posada D, Berman PW.

Mol Biol Evol. 2010 Feb;27(2):417-25. doi: 10.1093/molbev/msp254. Epub 2009 Oct 28.


Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial.

Pérez-Losada M, Posada D, Arenas M, Jobes DV, Sinangil F, Berman PW, Crandall KA.

Retrovirology. 2009 Jul 15;6:67. doi: 10.1186/1742-4690-6-67.


Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies.

O'Rourke SM, Schweighardt B, Scott WG, Wrin T, Fonseca DP, Sinangil F, Berman PW.

J Virol. 2009 Aug;83(15):7728-38. doi: 10.1128/JVI.00688-09. Epub 2009 May 27.


High incidence of unusual cysteine variants in gp120 envelope proteins from early HIV type 1 infections from a Phase 3 vaccine efficacy trial.

Jobes DV, Daoust M, Nguyen V, Padua A, Michele S, Lock MD, Chen A, Sinangil F, Berman PW.

AIDS Res Hum Retroviruses. 2006 Oct;22(10):1014-21. Erratum in: AIDS Res Hum Retroviruses. 2007 Jan;23(1):181.


Longitudinal population analysis of dual infection with recombination in two strains of HIV type 1 subtype B in an individual from a Phase 3 HIV vaccine efficacy trial.

Jobes DV, Daoust M, Nguyen VT, Padua A, Sinangil F, Pérez-Losada M, Crandall KA, Oliphant T, Posada D, Rambaut A, Fuchs J, Berman PW.

AIDS Res Hum Retroviruses. 2006 Oct;22(10):968-78. Erratum in: AIDS Res Hum Retroviruses. 2007 Jan;23(1):181.


HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.

Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, Hu DJ, Heyward WL, Sinangil F, Shepherd BE, Gurwith M.

J Infect Dis. 2005 Sep 15;192(6):974-83. Epub 2005 Aug 12.


Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW.

J Infect Dis. 2005 Mar 1;191(5):666-77. Epub 2005 Jan 27.


Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1.

Pitisuttithum P, Berman PW, Phonrat B, Suntharasamai P, Raktham S, Srisuwanvilai LO, Hirunras K, Kitayaporn D, Kaewkangwal J, Migasena S, Sheppard HW, Li E, Chernow M, Peterson ML, Shibata R, Heyward WL, Francis DP.

J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1160-5. Erratum in: J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1669.


Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials.

Francis DP, Heyward WL, Popovic V, Orozco-Cronin P, Orelind K, Gee C, Hirsch A, Ippolito T, Luck A, Longhi M, Gulati V, Winslow N, Gurwith M, Sinangil F, Berman PW.

AIDS. 2003 Jan 24;17(2):147-56. Review. No abstract available.


Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates.

Lee SA, Orque R, Escarpe PA, Peterson ML, Good JW, Zaharias EM, Berman PW, Sheppard HW, Shibata R.

Vaccine. 2001 Nov 12;20(3-4):563-76.


Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand.

Berman PW, Huang W, Riddle L, Gray AM, Wrin T, Vennari J, Johnson A, Klaussen M, Prashad H, Köhne C, deWit C, Gregory TJ.

Virology. 1999 Dec 5;265(1):1-9.


Secretion of glycosylation site mutants can be rescued by the signal/pro sequence of tissue plasminogen activator.

Köhne C, Johnson A, Tom S, Peers DH, Gehant RL, Hotaling TA, Brousseau D, Ryll T, Fox JA, Chamow SM, Berman PW.

J Cell Biochem. 1999 Dec 1;75(3):446-61.


HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Gorse GJ, Corey L, Patel GB, Mandava M, Hsieh RH, Matthews TJ, Walker MC, McElrath MJ, Berman PW, Eibl MM, Belshe RB.

AIDS Res Hum Retroviruses. 1999 Jan 20;15(2):115-32.


Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.

Francis DP, Gregory T, McElrath MJ, Belshe RB, Gorse GJ, Migasena S, Kitayaporn D, Pitisuttitham P, Matthews T, Schwartz DH, Berman PW.

AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S325-31. Review.


Development of bivalent rgp120 vaccines to prevent HIV type 1 infection.

Berman PW.

AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S277-89. Review.


Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers.

Berman PW, Gray AM, Wrin T, Vennari JC, Eastman DJ, Nakamura GR, Francis DP, Gorse G, Schwartz DH.

J Infect Dis. 1997 Aug;176(2):384-97.


Development of a single-shot subunit vaccine for HIV-1. 2. Defining optimal autoboost characteristics to maximize the humoral immune response.

Cleland JL, Barrón L, Berman PW, Daugherty A, Gregory T, Lim A, Vennari J, Wrin T, Powell MF.

J Pharm Sci. 1996 Dec;85(12):1346-9.


Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1.

Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG.

J Immunol. 1996 Dec 1;157(11):4986-95.


Supplemental Content

Loading ...
Support Center